<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin. Cancer Res.</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7367750</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7367750.1</article-id>
        <article-id pub-id-type="pmcaid">7367750</article-id>
        <article-id pub-id-type="pmcaiid">7367750</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1585617</article-id>
        <article-id pub-id-type="pmid">32299819</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3959</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1585617</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1585617</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hensley</surname>
              <given-names initials="ML">Martee L.</given-names>
            </name>
            <xref rid="FN1" ref-type="author-notes">*</xref>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chavan</surname>
              <given-names initials="SS">Shweta S.</given-names>
            </name>
            <xref rid="FN1" ref-type="author-notes">*</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A4">4</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Murali</surname>
              <given-names initials="R">Rajmohan</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Soslow</surname>
              <given-names initials="RA">Robert A.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chiang</surname>
              <given-names initials="S">Sarah</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jungbluth</surname>
              <given-names initials="AA">Achim A.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bandlamudi</surname>
              <given-names initials="C">Chaitanya</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Srinivasan</surname>
              <given-names initials="P">Preethi</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tap</surname>
              <given-names initials="WD">William D.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosenbaum</surname>
              <given-names initials="E">Evan</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Taylor</surname>
              <given-names initials="BS">Barry S.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A4">4</xref>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Donoghue</surname>
              <given-names initials="MTA">Mark T.A.</given-names>
            </name>
            <xref rid="FN2" ref-type="author-notes">#</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hyman</surname>
              <given-names initials="DM">David M.</given-names>
            </name>
            <xref rid="FN2" ref-type="author-notes">#</xref>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A2"><label>2</label>Weill Cornell Medical College, New York, NY</aff>
        <aff id="A3"><label>3</label>Marie-Jos√©e and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A4"><label>4</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A5"><label>5</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A6"><label>6</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A7"><label>7</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <author-notes>
          <fn id="FN1">
            <label>*</label>
            <p id="P1">Equal contributors</p>
          </fn>
          <fn id="FN2">
            <label>#</label>
            <p id="P2">Equal Contributors</p>
          </fn>
          <corresp id="CR1"><bold>Corresponding Author:</bold> Martee L. Hensley, M.D, M.Sc., FASCO, 300 E. 66<sup>th</sup> Street, office 1355, Memorial Sloan Kettering, New York, NY 10065, Phone: 646.888.4222, Fax: 646.888.4268, <email>hensleym@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN3">
            <p id="P38"><bold>Conflict of Interest Statement:</bold> DBS has consulted with/accepted honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Vivideon Therapeutics, Illumina and QED Therapeutics. Over the past 2 years, MLH has served on advisory boards for Tesaro and Lilly; has received author royalties from UpToDate; and has served as faculty speaker for Research to Practice. Also, her spouse is employed at Sanofi. B.S.T. reports advisory board activities for Boehringer Ingelheim and honoraria and research funding from Genentech.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>16</day>
          <month>4</month>
          <year>2020</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>15</day>
          <month>7</month>
          <year>2020</year>
        </pub-date>
        <volume>26</volume>
        <issue>14</issue>
        <issue-id pub-id-type="pmc-issue-id">361678</issue-id>
        <fpage>3881</fpage>
        <lpage>3888</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>23</day>
              <month>04</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>15</day>
              <month>01</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>15</day>
              <month>01</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-16 17:25:13.873">
              <day>16</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1585617.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose</title>
            <p id="P3">We examined whether prospective molecular characterization of advanced metastatic disease can reveal grade and/or histology-specific differences to inform diagnosis and facilitate enrollment onto clinical trials.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design</title>
            <p id="P4">Patients with uterine sarcoma consented to a prospective study of next-generation sequencing (NGS). Clinical annotations were extracted from their medical record. Tumor and matched normal DNA were subjected to NGS, and the genomic landscape was explored for survival correlations and therapeutic targetability.</p>
          </sec>
          <sec id="S3">
            <title>Results</title>
            <p id="P5">Tumors from 107 women were sequenced and included leiomyosarcoma (uLMS, n=80), high-grade non-LMS (n=22), low-grade endometrial stromal sarcoma (LG-ESS, n=4), and smooth muscle tumor of uncertain malignant potential (STUMP, n=2). Genomic profiling influenced histologic diagnosis in three cases. Common uterine LMS (uLMS) alterations were loss-of-function mutations in <italic toggle="yes">TP53</italic> (56%), <italic toggle="yes">RB1</italic> (51%), and <italic toggle="yes">ATRX</italic> (31%). Homozygous deletions of <italic toggle="yes">BRCA2</italic> were present in 5% of these patients. <italic toggle="yes">PTEN</italic> alteration frequency was higher in the metastases samples as compared to the primary samples. Genomes of low-grade tumors were largely silent, while 50.5% of high-grade tumors had whole genome duplication. Two metastatic uLMS cases were hypermutated. Both had prolonged disease-free survival. Potentially actionable mutations were identified in 48 patients (45%), eight (17%) of whom received matched therapy with two achieving clinical responses. Among uLMS patients with somatic <italic toggle="yes">BRCA2</italic> alterations, sustained partial responses were observed with PARP inhibitor-containing therapy.</p>
          </sec>
          <sec id="S4">
            <title>Discussion</title>
            <p id="P6">Prospective genomic profiling can contribute to diagnostic precision and inform treatment selection in patients with uterine sarcomas. There was evidence of clinical benefit in uLMS patients with somatic <italic toggle="yes">BRCA2</italic> alterations treated with PARP inhibitors.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>uterine cancer</kwd>
          <kwd>sarcoma</kwd>
          <kwd>genomic profiling</kwd>
          <kwd>next-generation sequencing</kwd>
          <kwd>precision medicine</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
